Navigation Links
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
Date:7/10/2009

ABBOTT PARK, Ill. and UPPSALA, Sweden, July 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Oasmia Pharmaceutical have announced a multi-year agreement to market one of the first cancer medications for dogs. The chemotherapeutic agent, called Paccal(R) Vet (micellar paclitaxel), represents the first generation of treatments of its kind and is currently being studied to treat Grade II and Grade III canine mast cell tumors where curative surgery cannot be performed.

Under the terms of the agreement, Abbott will obtain exclusive rights to distribute Paccal Vet for veterinary use in the United States and Canada, and will be responsible for sales and marketing. Oasmia is responsible for clinical development, manufacturing and registration. Financial terms were not disclosed.

Paccal Vet is a new formulation of the active ingredient paclitaxel. Paclitaxel has been used in treating cancer in humans since 1993. Traditional formulations of paclitaxel were insoluble in water, thus requiring the medication to be dissolved in solvents, which led to low tolerability and severe adverse effects in dogs. Paccal Vet uses a novel, non-toxic nanoparticle formulation that overcomes those challenges and provides a high level of water solubility. If approved, Paccal Vet would be one of the first cancer treatments specifically designed for veterinary use.

The move into veterinary oncology adds a new focus area to Abbott's existing Animal Health research and product lines, which include diabetes, anesthesia, wound care, pain management and fluid therapy.

"There are significant unmet needs in this market, which is why Abbott is entering the veterinary oncology arena," said Lynn Bromstedt, divisional vice president and general manager, Abbott Animal Health. "Paccal Vet would be one the first medications of its k
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Hosts Conference Call for Second-Quarter Earnings
2. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
3. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
4. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
5. Abbott Declares 342nd Consecutive Quarterly Dividend
6. Abbott Announces Launch of Next-Generation Embolic Protection System
7. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
8. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
9. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
10. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
11. Abbott to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Scottsdale, AZ (PRWEB) May 05, 2015 ... NCPDP’s Elite Partner Program. The program establishes a three-year ... to a maximum of 10 Elite Partners. “AmerisourceBergen has ... Ann Stember, President of NCPDP, “and this is a ... work. , We can trace AmerisourceBergen back to ...
(Date:5/5/2015)... 05, 2015 AxoGen, Inc. (NASDAQ: ... the $1.6 billion peripheral nerve repair market, reported record ... March 31, 2015 compared to $3.14 million in the ... of our proprietary portfolio of nerve repair products ... Nerve Protector – and our solid sales execution delivered ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Health IVF Clinic in Greece, an experienced team ... and treatment of infertility for patients around the globe. ... partnered with VisitandCare.com. Greece unquestionably remains a global leader ... most talented and hard-working fertility specialists in the world ...
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... York, New York (PRWEB) May 05, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on behalf ... complications due to their use of prescription ... in the federal multidistrict litigation underway in ... According to court documents dated May 1st, ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4
... 5, 2008 The American Cancer Society, the American ... Force on Colorectal Cancer (a group that comprises ... Gastroenterological Association, and American Society for Gastrointestinal Endoscopy) ... colorectal cancer screening. The guidelines add two new ...
... child,has a chronic illness is never easy, especially when ... it comes to physical,activities for children, most parents prefer ... experts say that may be a mistake. The spring ... Lupus Now(R), reports,that once a child,s lupus has been ...
... 5 Relax The Back corporation,sold a record number ... 16 franchised locations were sold last year, and 12 ... to deliver similarly,strong franchise sales results, with four stores ... another nine scheduled to open by June. The,company,s long-term ...
... Biopharmaceuticals using innovative technology in study of ... anti-infective ... today announced it has achieved another major milestone,in the management of ... The milestone EDC trial is a Phase II study being ...
... who rely on Community and Mission Hospital of Huntington ... go elsewhere as the,facility shuts its doors., The ... Mission. No new patients will be admitted and about ... its urgent care operations,last year., The Huntington Park ...
... decode the mind for therapeutic purposes , , WEDNESDAY, March 5 ... report they have found a way to "read" visual activity ... to scan the brain for activity information related to the ... of brain activity-image links is then created, so that future ...
Cached Medicine News:Health News:Health groups issue updated colorectal cancer screening guidelines 2Health News:Health groups issue updated colorectal cancer screening guidelines 3Health News:Child's Play - Lupus Now(R) Magazine Explores Activities for Children With a Chronic Condition 2Health News:Relax The Back Announces Record Growth in 2007; Executives Bullish on Specialty Retailer's Prospects for 2008 2Health News:Quintiles Data Management Surpasses 300 EDC Trials 2Health News:Community & Mission Hospital of Huntington Park Shutting Down Mission Campus, Terminating Workers 2Health News:Brain Scans Let Computer 'Read' Visual Activity 2Health News:Brain Scans Let Computer 'Read' Visual Activity 3
(Date:5/5/2015)... , May 5, 2015  Image Stream Medical, ... new agreement with MedAssets, one of the largest group ... the United States.  Under terms of the three-year agreement, ... and services will be made available to MedAssets members ... the partnership, Image Stream Medical CEO Eddie Mitchell ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing ... - Asia Pacific Version" report to their ... on growing. Clinical laboratory testing is positioned to ... genomics. A range of dynamic trends are pushing ...
(Date:5/5/2015)... are coming up with brilliant ways to help cannabis business solve problems and capitalize on opportunities. However not every idea makes ... ... ... ... Photo - http://photos.prnewswire.com/prnh/20150504/213635-INFO ...
Breaking Medicine Technology:Image Stream Medical Announces Agreement with MedAssets 2Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019 2Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4
... and National HIV/AIDS Elimination Act, NEW YORK, Oct. ... of,advancing prophetic social justice ministry, Black clergy are stepping,forward ... theologically,sound HIV/AIDS public policy. Working with the National Black ... up to the biblical,mandate that calls us to be ...
... Patient Subgroup Will Assess Safety and Anti-Viral ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company ... infection (HCV), today announced that the first patient,has been dosed in ...
Cached Medicine Technology:Statement From The National Conclave on HIV/AIDS Policy for Black Clergy 2Statement From The National Conclave on HIV/AIDS Policy for Black Clergy 3Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV 2Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV 3Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: